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Abstract
Introduction Current markers of Parkinson’s disease (PD) fail to detect the early progression of disease state. Conversely, 
current omics techniques allow the investigation of hundreds of molecules potentially altered by disease conditions. Based 
on evidence previously collected by our group in a mouse model of PD, we speculated that a particular set of circulating 
lipids might be significantly altered by the pathology.
Objectives The aim of current study was to evaluate the potential of a particular set of N-acyl-phosphatidylethanolamines 
(NAPEs) as potential non-invasive plasma markers of ongoing neurodegeneration from Parkinson’s disease in human subjects.
Methods A panel of seven NAPEs were quantified by LC–MS/MS in the plasma of 587 individuals (healthy controls, 
n = 319; Parkinson’s disease, n = 268); Random Forest classification and statistical modeling was applied to compare Par-
kinson’s disease versus controls. All p-values obtained in different tests were corrected for multiplicity by controlling the 
false discovery rate (FDR).
Results The results indicate that this panel of NAPEs is able to distinguish female PD patients from the corresponding healthy 
controls. Further to this, the observed downregulation of these NAPEs is in line with the results in plasma of a mouse model 
of Parkinson’s (6-OHDA).
Conclusions In the current study we have shown the downregulation of NAPEs in plasma of PD patients and we thus specu-
late that these lipids might serve as candidate biomarkers for PD. We also suggest a molecular mechanism, explaining our 
findings, which involves gut microbiota.
Keywords Parkinson’s disease · Lipid biomarkers · NAPE
1 Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder 
that affects motor functions and cognitive/neuropsychiat-
ric performances such as memory, speech, executive func-
tions, praxis, mood, thought and others. With the progres-
sive ageing of the population, the incidence of this condition 
is constantly increasing, causing a huge challenge for the 
healthcare systems. Epidemiological data suggest that in 
subjects above 60 years of age as many as 1% of the world-
wide population in the western countries are PD sufferers, 
with a rising prevalence associated to age. Moreover, PD is 
causing more than 100,000 deaths a year worldwide (Shul-
man et al. 2011). At present, PD can only be diagnosed 
when clinical symptoms are already detectable and thus 
proper medical treatment can only start when the disease 
is established, with a strong reduction in the efficiency of 
the therapeutic intervention. No validated PD molecular 
biomarkers are currently available for the clinical practice, 
although many have been proposed (Bolner et al. 2016; 
Gabriel et al. 2017; Pan et al. 2014; Peran et al. 2010). From 
this perspective, it would be highly beneficial to identify 
circulating molecules, easy to measure with a simple blood 
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test and highly correlated with progression and severity of 
neurodegeneration, which could serve as an early marker of 
the onset of disease. Given the role of lipids, particularly 
membrane lipids, in initiating the aggregation of alpha-
synuclein, which is considered to be the initial trigger for 
development of Parkinson’s disease (Ruiperez et al. 2010), 
recent literature supports the hypothesis that lipids in general 
might play a role in the development of the disease, par-
ticularly at its earlier stages. Some time ago, while testing 
a new setup for untargeted lipidomics, we found that in a 
mouse model of PD, i.e. the striatal injection of 6 hydroxy-
dopamine (6-OHDA), there is a strong upregulation of seven 
polyunsaturated phospholipids in the dorsal striatum as early 
as 48 h from disease induction (Basit et al. 2016). These 
lipids are N-acyl phosphatidylethanolamines, bearing either 
docohexaenoic (22:6) or arachidonic (20:4) acid residues 
in Sn2 position of the glycerol moiety and a stearic (18:0) 
or palmitic (16:0) acid acyl chain linked to ethanolamine 
(Coulon et al. 2012). Since these lipids can relatively easily 
be measured in plasma, we expanded the study by quantify-
ing the same set of lipids in plasma of 6-OHDA animals, 
at the same early stage timepoint (48 h), Finally, given the 
potential of our findings in the context of PD diagnosis, we 
conducted an exploratory study, by measuring the levels of 
these lipids in the plasma of a group of human subjects diag-
nosed with PD.
2  Methods
2.1  Animal experiments
Male 8–10 weeks old mice were anesthetized with a mix-
ture of ketamine/xylazine (100 and 10 mg/kg body weight, 
respectively) and placed in a stereotaxic frame with a 
mouse-adaptor (Stoelting, Wood Dale, USA). 6-hydroxy-
DA was dissolved at a concentration of 3.2 μg/μL of ice-
cold 0.9% saline solution containing 0.02% ascorbate. Two 
injections of 1 μL each were made at the following brain 
atlas coordinates (in mm relative to bregma and dural sur-
face, Paxinos and Franklin 2001): (i) AP = + 1.0, L = − 2.1, 
DV = − 2.9; and (ii) AP = + 0.3, L = − 2.3, DV = − 2.9. Sham 
lesions were carried out by 1 μL injection of 0.02% ascor-
bic acid-saline at the same coordinates. Forty-eight hours 
after 6-hydroxy-DA injection, mice were anesthetized with 
chloral hydrate (450 mg/kg) and killed by decapitation; the 
blood was collected and plasma was separated and stored 
at − 80 °C until analysis. (Basit et al. 2016). All procedures 
were performed in compliance with Italian regulations on 
protection of animals used for experimental and other sci-
entific purposes (D.M. 116192) as well as with European 
Economic Community regulations (O.J. of E.C. L 358/1 
12/18/1986). The study was approved by the Italian Ministry 
of Health with code n° 095 for Istituto Italiano di Tecnolo-
gia, Animal Facility.
2.2  Recruitment of human subjects
PD participants were assessed at the Laboratory of Neu-
ropsychiatry of the I.R.C.C.S. Santa Lucia Foundation in 
Rome. Inclusion criteria for PD patients were: (i) diagnosis 
of idiopathic PD according to the international guidelines 
(Folstein et al. 1975) (ii) Mini Mental State Examination 
(MMSE) score > 26 (Emre et al. 2007) (iii) no dementia 
according to the Movement Disorder Society clinical diag-
nostic criteria (Iorio et al. 2013) using an extensive neu-
ropsychological battery. Exclusion criteria were (1) presence 
of major non stabilized medical illnesses (i.e., nonstabilized 
diabetes, obstructive pulmonary disease or asthma, hemato-
logic/oncologic disorders, vitamin B12 or folate deficiency, 
pernicious anemia, clinically significant and unstable active 
gastrointestinal, renal, hepatic, endocrine or cardiovascular 
disorders and recently treated hypothyroidism. (2) known 
or suspected history of alcoholism, drug dependence and 
abuse, head trauma, and mental disorders (apart from mood 
or anxiety disorders) according to the DSM-IV TR criteria 
[American Psychiatric Association (2000): Diagnostic and 
Statistical Manual of Mental Disorders, 4th ed. Washington, 
DC: Task Force. (3) history of neurological diseases other 
than idiopathic PD. (4) unclear history of chronic dopamin-
ergic treatment responsiveness. (5) MRI scans lacking signs 
of focal lesions as computed according to the semi-auto-
mated method recently published by our group (McKhann 
et al. 2011) (minimal diffuse changes or minimal lacunar 
lesions of white matter (WM) were, however, allowed). 
All included PD patients were under stable dopaminergic 
therapy and were at stage I or II of the disease. Furthermore, 
they were not receiving deep brain stimulation and were not 
under continuous dopaminergic stimulation by subcutaneous 
apomorphine or intrajejunal L-Dopa. Inclusion criteria for 
control subjects were: (i) vision and hearing sufficient for 
compliance with testing procedures; (ii) laboratory values 
within the appropriate normal reference intervals; and (iii) 
neuropsychological domain scores above the cutoff scores, 
corrected for age and educational level, identifying normal 
cognitive level in the Italian population. Exclusion criteria 
were (i) dementia diagnosis, according with DSM-IV crite-
ria or MCI according with Petersen criteria, and confirmed 
by a comprehensive neuropsychological battery and (ii) 
MMSE score < 26 according with standardized norms for the 
Italian population (Dellasega and Morris 1993). At recruit-
ment, patients fulfilled an anamnestic interview including 
information about major medical illnesses (including neu-
rological conditions other than PD), substance abuse, pres-
ence of primary psychiatric disorders, dopaminergic treat-
ment responsiveness, presence of cerebrovascular disease. 
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Patients were also screened for the presence of dementia. 
After blood sampling, patients’ identity was masked by a 
random code and all personal information were deleted. 
The study was approved and financially supported by the 
Italian Ministry of Health (Grant RF-2013-02359074). All 
the participants or related caretakers gave their written con-
sent to the enrollment. The present study was approved by 
the Ethical Committee of IRCCS Santa Lucia Foundation 
(CE-AG4-Prog.149).
2.3  Human blood sample collection
Blood samples (10 ml) from all participants were, after over-
night fasting (11 ± 1 h), collected from forearm veins in BD 
Vacutainer tubes containing ethylenediaminetetracetic acid 
(Beckton Dickinson, Franklin Lakes, NJ). Plasma aliquots 
were prepared by centrifugation at 3000 rpm at 4 °C for 
15 min and stored at − 80 °C until analysis.
2.4  NAPE quantification
NAPEs were extracted from 0.1 ml of plasma samples with 
1 ml of ethanol containing the synthetic exogenous 18:0-
22:6-N17:0 NAPE as an internal standard. The solution was 
vortexed for 1 min then centrifuged at 3500 g at 4 °C for 
10 min. The supernatant was then collected and dried under 
nitrogen stream. The dried samples were then resuspended in 
0.1 ml of 9:1 MeOH/CHCl3 solution for LC–MS/MS analy-
sis. Targeted analysis of the samples was then carried out on 
an Acquity UPLC system coupled with a Xevo TQ-MS triple 
quadrupole mass spectrometer. Full details of the analytical 
method are given in the Supplementary Data file. The sam-
ples were analyzed over a broad time span (December 2015 
to March 2017) in a randomized order, acquiring the same 
number of controls and disease subjects in each analytical 
session. Despite the high reproducibility of the analytical 
method, some residual batch effect was visible in the overall 
dataset. To compensate for that, a specific batch removal 
strategy was implemented and it is discussed in the Sup-
plementary Method file.
2.5  Statistics
All statistical analyses were performed in R (https ://www.R-
proje ct.org/). Welch t-test was applied to statistically com-
pare 6-OHDA versus sham mice. The concentration of 
the metabolites were log transformed to correct for the 
heteroscedasticity typical of metabolomics data (van den 
Berg et al. 2006). A generalized linear modeling (GLM) 
approach (Venables and Ripley 2002) was used to compare 
PD patients versus control subjects. In order to relate the 
intercept of the model to the average concentration of the 
lipids in the samples, the variable ‘age’ was mean centered 
and scaled (Gelman and Hill 2007). All p values obtained in 
the different tests were corrected for multiplicity by applying 
a False Discovery Rate (FDR) (Franceschi et al. 2013). Mul-
tivariate data analysis was performed by applying Random 
Forests classification separately to male and female subjects. 
A classification tree based approach was selected because 
the importance of the individual variables (the individual 
NAPEs and the Age) can be naturally inspected at the end 
of the model optimization phase. To avoid overfitting, the 
following validation scheme was used. (1) the overall dataset 
was repeatedly (100 times) split in training and test subsets 
(0.8, 0.2) and separate Random Forests models were fit on 
the data. (2) The performance of each model was assessed 
in terms of the AUC of the ROC curve built on the test sam-
ple. (3) As an additional validation step, the same scheme 
was applied to 100 random permutation of the sample class 
labels. The classifier parameter ‘mtry’ (Number of variables 
randomly sampled as candidates at each split) was optimized 
by five-fold repeated cross validation (3 times) by using the 
caret R package. As in many tree-based approaches, the vari-
able importance in Random Forests was assessed by consid-
ering how much a single variable is effective in splitting the 
data in “pure” classes. The purity of the classes was meas-
ured in terms of the Gini impurity index (Wehrens 2011). 
The index considers values in the [0,1] interval: lower values 
are associated with higher levels of purity. Important vari-
ables are then those able to produce the strongest decrease 
in the Gini index when “included” in the model. Since Ran-
dom Forests relies on the construction of a large number of 
trees, the decrease in Gini is averaged across all the trees 
which are including a specific variable, so that the variable 
importance is assessed in terms of Mean Decrease of Gini 
index. In our validation scheme, each one of the training-test 
splits was producing an independent model with its own 
variable importance measure. The individual values were 
finally combined calculating the medians of each variable 
importance and estimating the variability of this importance 
in terms of the 5 and 95 percentiles of the empirical distribu-
tion of mean decrease in Gini index. Random Forest clas-
sification analysis (Breiman 2001) was performed by using 
R Random Forest package.
3  Results and discussion
In a recent paper (Basit et al. 2016) we described the strong 
upregulation of seven Sn2-polyunsaturated (20:4 or 22:6) 
N-acyl-phosphatidylethanolamines (NAPEs) occurring in 
the dorsal striatum of mice 48 h after unilateral injection 
of 6-OHDA in the striatum. This neurotoxic model for PD 
is very popular and useful to explore the molecular mecha-
nisms of the disease (Bove et al. 2005). It has a series of 
advantages: the less extensive lesion (Przedborski et al. 
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1995) compared to other models, closer to PD, the ability 
to promote also non-motor symptoms and the likeliness of 
injection success (Sauer and Oertel 1994). Conversely, like 
other neurotoxic models, the response greatly depends on 
the injection success; this often generates high variabil-
ity in the animal response to the toxin. Furthermore, the 
6-OHDA model lacks the progressive and age-dependent 
effects of PD and it does not lead to the formation of Levy 
bodies (Tieu 2011). Bearing in mind all these cautions, we 
then tried to investigate if the NAPEs increase observed in 
the brain was accompanied by some alteration at peripheral 
level, and we sampled the plasma of the same animals at 
the same 48 h timepoint. We quantified the panel of seven 
NAPEs in plasma by using a slightly modified version of 
the method already described (Basit et al. 2016). The full 
description of the analytical method is reported in the Sup-
plementary information. Rather unexpectedly, we observed 
a general trend for downregulation of these lipids in the 
6-OHDA animals, with two NAPEs (16:0-22:6-N18:0 and 
18:0-22:6-N16:0) being highly significantly downregulated 
in the plasma of 6-OHDA treated animals compared to the 
sham animals (surgery was done but no toxin was injected). 
The results are reported in Fig. 1.
Two out of the seven lipids show a significant decrease 
at the 0.05 level and one at the 0.15 level. The spread of 
the red points in the plot indicates that 6-OHDA treatment 
induced a stronger variability in the concentration of plasma 
lipids compared to control animals (sham, purple dots). The 
animals were sacrificed only 48 h after the injection and 
none of them was showing any PD symptoms, that normally 
occur 2 to 3 weeks after the insult (Przedborski et al. 1995). 
The results obtained for brain and plasma might suggest that 
6-OHDA treatment alters the systemic levels of NAPEs and 
the increase in brain concentration is accompanied by a 
decrease in peripheral levels. We then decided to perform 
an exploratory study, by conducting a targeted metabolomics 
experiment. We measured the levels of these seven lipids 
in the plasma of a large cohort of subjects diagnosed with 
Parkinson’s disease and we compared them with the levels 
of a group of healthy subjects. No preliminary hypothesis 
was formulated for this experiment, as we wanted to explore 
any possible association between circulating NAPE levels 
and PD diagnosis. These subjects represent a generic popu-
lation of PD patients or control subjects and no control on 
diet (other than overnight fasting before the blood with-
drawal) was applied. It was not even possible to collect data 
on BMI values of these individuals or information on their 
lifestyle. Conversely, none of the PD patients, or their related 
caregiver, at the time of sampling reported any significant 
change in their usual diet following the diagnosis. The final 
patient distribution and sociodemographic data are reported 
in Table 1.
Supplementary Datafile 1 reports the full set of raw 
data from this human study; the concentration values 
were again Log transformed. As shown in Supplementary 
Fig. 1, the distribution of healthy controls spans over a 
broader range compared to PD patients. To correct for 
this, a different set of healthy controls (Age > 40) was 
Fig. 1  Results of a 2-tails t-test (with FDR correction for multi-
ple testing) comparing the levels of seven NAPEs in the plasma of 
male mice treated with 6-OHDA, sampled 48  h after the injection, 
with those of sham animals (surgery but no toxin injection). Data 
were Log transformed and refer to 6 treated versus 5 control animals 
(sham). Concentration data are Log transformed
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considered during the statistical analysis, thus age match-
ing the two groups. Supplementary Datafile 2 reports the 
final set of data used for the analysis after the rebalancing 
of the sample set and the batch effect removal. Table 2 
reports the dataset composition after age matching.
The predictive potential of the proposed NAPE panel 
for the PD diagnosis was evaluated by Random Forest. In a 
recent systematic review and meta-analysis that investigated 
gender dependence in PD incidence (Hirsch et al. 2016), 
it has been demonstrated that while male subjects have a 
higher incidence of PD in all age groups, this difference is 
only statistically significant for women in age ranges 60–69 
and 70–79. A potential explanation for the increased inci-
dence in males not causing a parallel increase in prevalence 
is the more benign course of the disease in females, specu-
lated to be caused by higher estrogen activity, which leads to 
higher dopamine levels in the striatum (Hirsch et al. 2016). 
Based on this evidence, and thus considering that the general 
risk of developing PD increases with age, we also added 
the subject’s age as a further variable to the RF model. As 
the original dataset was not well balanced for gender (F/M 
ratio: 1.2 for controls and 0.8 for PD), we performed two 
separated, independent analyses for female and male sub-
jects. The corresponding AUC values were calculated for 
both genders, as reported in Fig. 2.
The corresponding ROC curves at 95% confidence inter-
val were also calculated and are reported in Supplementary 
Fig. 2. Our data indicate that the proposed panel of seven 
NAPEs and the variable “age” can be used to predict the 
patient status better than a random classifier for both gen-
ders. While for males the performance compared to the ran-
dom classifier is quite low, the predicting power of NAPEs 
for PD in female subjects appears to be much stronger, thus 
suggesting that the panel of NAPEs is able to distinguish 
PD in women with higher specificity than in men. We then 
explored the importance of the individual variables on the 
Table 1  Sociodemographic and clinical characteristics of males and 
females with Parkinson’s disease and healthy control subjects
Control subjects Parkinsons’s disease
Female 177 117
Male 142 151
Age (average-span) 52 (19–90) 63 (35–86)
Education 14.2 (5–27) 11.2 (5–25)
MMSE score 29.3 (26–30) 28.6 (26–30)
Table 2  Distribution of male and female subjects in the final dataset 
used for the study
Total Control subjects Parkin-
sons’s 
disease
Female 256 142 114
Male 263 114 149
Fig. 2  AUC values calculated 
for the selected panel of NAPEs 
compared to a random classifier 
for both male (green dots) and 
female (blue dots) subjects. 
Each point corresponds to the 
AUC calculated for an inde-
pendent training-test split
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overall model performance (see Sect. 2). Figure 3 reports 
the corresponding Variable Importance Plot for our clas-
sification model.
In the plot, the importance of each variable is evaluated 
in terms of mean decrease in Gini Index (Wehrens 2011), 
highlighting the median value and the 95% confidence 
intervals in the 100 independent training/test splits. The 
full description of the model validation is reported in the 
Methods section. As clearly indicated by the plot, for male 
subjects, age (in red) is the most import variable for the 
model, while in female subjects, the importance of age in the 
model is limited and much lower than that of at least three 
circulating NAPEs (P16:0/22:6/N18:0), (18:0/22:6/N18:0), 
(18:0/20:4/N18:0). Both plots, show a comparable effects 
of the variables included in the model, thus suggesting that 
the combination of Age and NAPEs can be effective in pre-
dicting the disease status. It should be noted here that BMI 
might represent a potential confounding factor in our study, 
as NAPEs are mostly introduced with or produced from diet. 
Several papers show that BMI increases with age (Thevenot 
et al. 2015) and that, on average, it is higher in males that in 
females (Krumsiek et al. 2015; Trabado et al. 2017). Con-
versely, recent studies suggest that high BMI and obesity 
are not associated with Parkinson’s (Roos et al. 2018) and 
that higher BMI might be potentially protective toward PD 
(Noyce et al. 2017). We can then conclude that there is no 
reported evidence for higher BMI values in PD population 
and thus our conclusion on the potential of NAPEs for PD 
diagnosis in female patients still holds true. While our clas-
sification analysis confirms that the panel of lipids is useful 
to predict the disease state, it is not giving any information 
on the effect of the disease on the concentration of the single 
lipids. In addition, the presence of ‘age’ among the most 
predictive variables, suggests the possible presence of an 
age dependent effect on the concentration of the measured 
metabolites. In order to take into consideration this effect 
and investigate the effect of the disease on the concentration 
of the circulating lipids, the NAPE concentrations for male 
and female subjects were analyzed by using a linear model 
approach (Kreidler et al. 2013), explicitly including age as 
predictor in the model. Male and female subjects were ana-
lyzed independently, to account for the gender imbalance in 
the dataset. The results of the modeling of the seven lipids 
are presented in Fig. 4, which shows the average concentra-
tion of each lipid (corrected for age trends) in PD patients 
compared to the average concentration in healthy controls 
(set to zero).
Only parameters showing a p value lower than 0.1 after 
FDR correction were considered significant. Six out of seven 
lipids are significantly lower in both male and female PD 
subjects. NAPE 16:0-22:6-N18:0, is significantly decreased 
in PD compared with controls for male subjects only. The 
plots indicate that, for every lipid, the average concentration 
is lower in the disease state than in the controls, similarly 
to what we observed in the 6-OHDA mouse model of PD. 
From a translational perspective, the two lipids that are sig-
nificantly downregulated in male mice (16:0-22:6-N18:0 and 
18:0-22:6-N16:0) are also significantly downregulated in the 
plasma of male PD patients.
3.1  A putative mechanism
NAPEs are precursors of lipid messengers but also important 
signaling molecules per se (Coulon et al. 2012). They are 
naturally ubiquitous in mammalian tissues (Petersen et al. 
2005). Intriguingly, NAPEs have been shown to accumulate 
in tissues where degeneration is ongoing (Hansen et al. 1997, 
2001). Based on our observation in mouse brain, we can 
Fig. 3  Variable Importance 
plots for the predictive model 
based on the plasma concentra-
tion of the seven NAPEs and the 
“age” factor. The importance 
of each variable is assessed in 
terms of Mean Decrease of Gini 
impurity index (see Sect. 2 for 
details). The horizontal seg-
ments indicate the 95 confi-
dence intervals for each variable 
importance over the independ-
ent 100 models
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thus speculate that their levels are higher also in PD human 
brains. Conversely, we now know that their levels are gener-
ally lower in PD patients’ plasma, and this is in line with our 
observations in 6-OHDA mouse plasma. We thus believe 
that central neurodegeneration causes a structural damage 
to neurons that is counterbalanced by an increased recruit-
ment of NAPEs from blood. The aim of this redistribution 
would be to maintain cell membrane integrity and counteract 
cell death: indeed, several authors report that NAPEs, given 
their peculiar structure, play a crucial role in maintaining 
the biophysical integrity of biological membranes, espe-
cially in the central nervous system (Hansen et al. 1997). 
As a further supporting evidence to our hypothesis, it has 
already been demonstrated by using radiolabeled compounds 
that NAPEs deriving from food are actively recruited from 
the gut into the brain (Gillum et al. 2008) passing through 
the blood–brain barrier. It is also known that these lipids 
are synthesized in the small intestine (Gillum et al. 2008) 
also with the active participation of gut microbiota (Fu et al. 
2007). Furthermore, recent data suggest that gut microbiota 
is crucial in neurodegeneration (Erny and Prinz 2017; Jiang 
et al. 2017; Mancuso and Santangelo 2017). This evidence 
itself might represent a link between our observations on 
NAPEs and the demonstrated role of gut microbiota on neu-
rodegeneration. Our proposed scenario is that the altered gut 
microbiota of PD patients is not able to fully restore blood 
levels of NAPEs and thus is only partially able to contribute 
to the rebalancing of brain NAPEs. Nothing is known about 
the kinetics of this periphery/brain rebalancing and this 
deserves further investigations. The early stage effect that 
we observe in mice might be very different from phenomena 
occurring in patients, where the brain damage is progressive 
and associated to aging.
4  Conclusions
Based on present findings, we can conclude that the down-
regulation of particular circulating NAPE species might have 
the potential to become a candidate biomarker for PD in 
female subjects. Our study shows, indeed, that NAPEs are 
significantly downregulated in the plasma of PD patients, 
with gender-specific profiles. To the best of our knowledge, 
this observation has never been reported before. We are also 
hereby proposing a simple molecular mechanism that might 
explain our findings. Transfer of NAPEs from circulating 
plasma to CNS appears to be not only plausible, but it has 
been already reported by others (Gillum et al. 2008). In the 
perspective of a future use of these lipids as biomarkers for 
PD, it could be argued that the average AUC values obtained 
with the ROC analysis in female subjects (0.75–0.85), are 
not sufficient to propose a highly specific analytical test 
potentially interesting in a clinical context. Furthermore, as 
discussed above, the absence of BMI data might represent 
a potential confounder in our work. However, considering 
that NAPEs are exclusively introduced or synthesized from 
food intake, it is remarkable that a clear effect is visible in 
a cohort of patients not stratified for BMI, diet and lifestyle. 
We thus believe that the present explorative work has pro-
duced ground for further extensive cross-validation works, 
with a more stringent control of patient stratification, also 
based on diet-related data like BMI. This is required to 
Fig. 4  Gender-dependent 
downregulation of each NAPE 
in PD. The plot shows the 
average plasma concentration 
of each lipid (corrected for 
age) in males and females PD 
compared to controls subjects 
(whose average value is set to 
zero, dotted line). All the trends 
are significant (p < 0.1 after 
FDR correction) except for: 
16:0-22:6-N18:0, not significant 
for Female subjects
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confirm the potential of NAPE lipids as candidate biomark-
ers for PD. We also believe that plasma NAPEs, being a 
relatively simple readout, might represent a valuable tool 
for pharmacological research and PD, if proven to be associ-
ated to disease progression and recovery. Furthermore, the 
link between NAPEs, diet and gut microbiome envisages a 
possible role of nutrition and bacterial engineering (Dosoky 
et al. 2017) as potential therapeutic opportunities to act on 
circulating NAPE levels and possibly restore or contrast 
CNS degeneration.
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